<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Combination chemotherapy regimen incorporating CD20 antibodies are commonly used in the treatment of CD20-positive non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) </plain></SENT>
<SENT sid="1" pm="."><plain>Fludarabine phosphate (F-araAMP), <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, and CD20 antibodies (Rituximab) constitute the FCR regimen for treating selected NHL, including aggressive mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>As an alternative to the CD20 antibody, we generated a CD20-targeted <z:e sem="disease" ids="C0025007" disease_type="Disease or Syndrome" abbrv="">measles</z:e> virus (MV)-based vector </plain></SENT>
<SENT sid="3" pm="."><plain>This vector was also armed with the <z:chebi fb="0" ids="50266">prodrug</z:chebi> convertase <z:chebi fb="0" ids="26394">purine nucleoside</z:chebi> phosphorylase (PNP) that locally converts the active metabolite of F-araAMP to a highly diffusible substance capable of efficiently killing bystander cells </plain></SENT>
<SENT sid="4" pm="."><plain>We showed in infected cells that early <z:chebi fb="0" ids="50266">prodrug</z:chebi> administration controls vector spread, whereas late administration enhances cell killing </plain></SENT>
<SENT sid="5" pm="."><plain>Control of spread by early <z:chebi fb="0" ids="50266">prodrug</z:chebi> administration was also shown in an animal model: F-araAMP protected genetically modified mice susceptible to MV <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> from a potentially lethal intracerebral challenge </plain></SENT>
<SENT sid="6" pm="."><plain>Enhanced oncolytic potency after extensive <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> was shown in a Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> (Raji cells): After systemic vector inoculation, <z:chebi fb="0" ids="50266">prodrug</z:chebi> administration enhanced the therapeutic effect synergistically </plain></SENT>
<SENT sid="7" pm="."><plain>In a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> (Granta 519 cells), intratumoral (i.t.) vector administration alone had high oncolytic efficacy: <z:hpo ids='HP_0000001'>All</z:hpo> mice experienced complete but temporary <z:mp ids='MP_0010537'>tumor regression</z:mp>, and survival was two to four times longer than that of untreated mice </plain></SENT>
<SENT sid="8" pm="."><plain>Cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> patients were shown to be sensitive to <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, synergy of F-araAMP with a PNP-armed and CD20-targeted MV was shown in one <z:hpo ids='HP_0002665'>lymphoma</z:hpo> therapy model after systemic vector inoculation </plain></SENT>
</text></document>